GMAB Latest Press Releases

-- November 4, 2026 --

Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting Business Wire 9:00 AM

-- October 28, 2026 --

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer Business Wire 9:41 AM

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer Globe Newswire 9:40 AM

-- October 26, 2026 --

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market Globe Newswire 9:00 AM

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Business Wire 7:00 AM

-- October 25, 2026 --

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer Business Wire 7:00 AM

-- October 24, 2026 --

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer Business Wire 7:01 AM

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer Business Wire 7:00 AM

-- October 23, 2026 --

Genmab Announces Rinatabart Sesutecan (Rina-S) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer Business Wire 11:56 AM

Genmab Announces Rinatabart Sesutecan (Rina-S) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer Globe Newswire 11:55 AM

-- October 13, 2026 --

Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2026 Globe Newswire 6:22 AM

-- October 5, 2026 --

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma PRNewswire 2:55 PM

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Business Wire 2:50 PM

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Globe Newswire 2:49 PM

-- October 3, 2026 --

Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL -01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer Business Wire 3:40 PM

-- October 2, 2026 --

Major Shareholder Announcement Globe Newswire 1:49 PM

-- July 23, 2026 --

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Business Wire 4:00 PM

-- July 15, 2026 --

Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2026 Globe Newswire 6:22 AM

-- July 6, 2026 --

Genmab Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma Business Wire 1:45 PM

-- June 29, 2026 --

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival Business Wire 4:15 PM

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival Globe Newswire 4:14 PM

-- June 15, 2026 --

Major Shareholder Announcement Globe Newswire 12:04 PM

-- June 13, 2026 --

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Business Wire 12:45 PM

-- June 11, 2026 --

Genmab Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients Business Wire 10:45 AM

Market Data Delayed 15 Minutes